Publikationen in Zusammenarbeit mit Forschern von Hospital Universitari Germans Trias i Pujol (14)

2024

  1. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

    Journal of Clinical Medicine, Vol. 13, Núm. 3

2022

  1. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19

    American Journal of Hematology

  2. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

  3. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

    Leukemia, Vol. 35, Núm. 2, pp. 485-493

  2. Long-term follow-up of recovered MPN patients with COVID-19

    Blood Cancer Journal

  3. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

    Blood Cancer Journal

2020

  1. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

    Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158

  2. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes

    Journal of Molecular Diagnostics, Vol. 22, Núm. 10, pp. 1217-1224

2018

  1. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis

    Leukemia

2017

  1. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

    European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414

2016

  1. Long-term results of prednisone treatment for the anemia of myelofibrosis

    Leukemia and Lymphoma, Vol. 57, Núm. 1, pp. 120-124

2015

  1. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

    Annals of Hematology, Vol. 94, Núm. 6, pp. 911-918

2014

  1. The international prognostic scoring system does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

    Haematologica